ENLIVEN THERAPEUTICS INC (ELVN) Fundamental Analysis & Valuation

NASDAQ:ELVN • US29337E1029

Current stock price

35.53 USD
+4.38 (+14.06%)
At close:
35.8 USD
+0.27 (+0.76%)
Pre-Market:

This ELVN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ELVN Profitability Analysis

1.1 Basic Checks

  • In the past year ELVN has reported negative net income.
  • ELVN had a negative operating cash flow in the past year.
  • ELVN had negative earnings in 4 of the past 5 years.
  • In the past 5 years ELVN always reported negative operating cash flow.
ELVN Yearly Net Income VS EBIT VS OCF VS FCFELVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • With a Return On Assets value of -21.78%, ELVN perfoms like the industry average, outperforming 59.59% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -22.56%, ELVN is in the better half of the industry, outperforming 67.88% of the companies in the same industry.
Industry RankSector Rank
ROA -21.78%
ROE -22.56%
ROIC N/A
ROA(3y)-25.15%
ROA(5y)-25.7%
ROE(3y)-26.8%
ROE(5y)-27.62%
ROIC(3y)N/A
ROIC(5y)N/A
ELVN Yearly ROA, ROE, ROICELVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ELVN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELVN Yearly Profit, Operating, Gross MarginsELVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ELVN Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ELVN has been increased compared to 1 year ago.
  • Compared to 5 years ago, ELVN has more shares outstanding
  • ELVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ELVN Yearly Shares OutstandingELVN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
ELVN Yearly Total Debt VS Total AssetsELVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • ELVN has an Altman-Z score of 76.25. This indicates that ELVN is financially healthy and has little risk of bankruptcy at the moment.
  • ELVN's Altman-Z score of 76.25 is amongst the best of the industry. ELVN outperforms 97.93% of its industry peers.
  • ELVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 76.25
ROIC/WACCN/A
WACCN/A
ELVN Yearly LT Debt VS Equity VS FCFELVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 28.66 indicates that ELVN has no problem at all paying its short term obligations.
  • ELVN has a Current ratio of 28.66. This is amongst the best in the industry. ELVN outperforms 96.89% of its industry peers.
  • ELVN has a Quick Ratio of 28.66. This indicates that ELVN is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ELVN (28.66) is better than 96.89% of its industry peers.
Industry RankSector Rank
Current Ratio 28.66
Quick Ratio 28.66
ELVN Yearly Current Assets VS Current LiabilitesELVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ELVN Growth Analysis

3.1 Past

  • ELVN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.59%.
EPS 1Y (TTM)1.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ELVN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.40% on average per year.
  • ELVN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 734.04% yearly.
EPS Next Y-7.69%
EPS Next 2Y-20.92%
EPS Next 3Y-7.1%
EPS Next 5Y17.4%
Revenue Next Year-100%
Revenue Next 2Y32.31%
Revenue Next 3Y20.52%
Revenue Next 5Y734.04%

3.3 Evolution

ELVN Yearly Revenue VS EstimatesELVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ELVN Yearly EPS VS EstimatesELVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20

More info and screens

Find the best growth stocksShow best growing peers

0

4. ELVN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ELVN. In the last year negative earnings were reported.
  • Also next year ELVN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELVN Price Earnings VS Forward Price EarningsELVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELVN Per share dataELVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as ELVN's earnings are expected to decrease with -7.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.92%
EPS Next 3Y-7.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ELVN Dividend Analysis

5.1 Amount

  • No dividends for ELVN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ELVN Fundamentals: All Metrics, Ratios and Statistics

ENLIVEN THERAPEUTICS INC

NASDAQ:ELVN (3/25/2026, 8:23:35 PM)

Premarket: 35.8 +0.27 (+0.76%)

35.53

+4.38 (+14.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-03
Earnings (Next)05-12
Inst Owners92.99%
Inst Owner Change7.67%
Ins Owners8.42%
Ins Owner Change0.93%
Market Cap2.12B
Revenue(TTM)N/A
Net Income(TTM)-103.69M
Analysts85
Price Target41.59 (17.06%)
Short Float %17.31%
Short Ratio7.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.55%
Min EPS beat(2)-24.57%
Max EPS beat(2)27.67%
EPS beat(4)2
Avg EPS beat(4)0.59%
Min EPS beat(4)-24.57%
Max EPS beat(4)27.67%
EPS beat(8)6
Avg EPS beat(8)6.86%
EPS beat(12)7
Avg EPS beat(12)2.33%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-8.62%
EPS NQ rev (3m)-8.62%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.62
P/tB 4.62
EV/EBITDA N/A
EPS(TTM)-1.86
EYN/A
EPS(NY)-2
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0
BVpS7.69
TBVpS7.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.78%
ROE -22.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.15%
ROA(5y)-25.7%
ROE(3y)-26.8%
ROE(5y)-27.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.08%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 28.66
Quick Ratio 28.66
Altman-Z 76.25
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)41.37%
Cap/Depr(5y)38.63%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.35%
EPS Next Y-7.69%
EPS Next 2Y-20.92%
EPS Next 3Y-7.1%
EPS Next 5Y17.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y32.31%
Revenue Next 3Y20.52%
Revenue Next 5Y734.04%
EBIT growth 1Y-14.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.12%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.95%
OCF growth 3YN/A
OCF growth 5YN/A

ENLIVEN THERAPEUTICS INC / ELVN Fundamental Analysis FAQ

What is the fundamental rating for ELVN stock?

ChartMill assigns a fundamental rating of 3 / 10 to ELVN.


What is the valuation status of ENLIVEN THERAPEUTICS INC (ELVN) stock?

ChartMill assigns a valuation rating of 0 / 10 to ENLIVEN THERAPEUTICS INC (ELVN). This can be considered as Overvalued.


How profitable is ENLIVEN THERAPEUTICS INC (ELVN) stock?

ENLIVEN THERAPEUTICS INC (ELVN) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for ELVN stock?

The Earnings per Share (EPS) of ENLIVEN THERAPEUTICS INC (ELVN) is expected to decline by -7.69% in the next year.